Hematologic Malignancies

Filter By:
04:06
A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance...
by:EMJ | 57 views
05:19
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a phase II trial that evaluated selective photodepletion of recipient-allor​eactive T-cells (ATIR) for haploidentical haematopoietic stem cell transplant in patien...
by:EMJ | 77 views
03:15
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses recent advances in the treatment of multiple myeloma. The phase III ASPIRE study showed that adding the proteasome inhibitor, carfilzomib, to the standard doublet therapy of...
by:EMJ | 259 views
23:32
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Catherine Bollard (Children's National Medical Center, Washington, DC), Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA), Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY), Dr Nicola Gökbuget (Un...
by:EMJ | 144 views
06:39
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) presents the results of a study that suggests chimeric antigen receptor (CAR) T cells targeting CD19 (CTL...
by:EMJ | 186 views
05:37
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Joseph Alvarnas (City of Hope National Medical Center, Duarte, CA) presents data from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial, which...
by:EMJ | 134 views
07:23
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-au...
by:EMJ | 177 views
13:22
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Steensma (Dana-Farber Cancer Institute, Boston, MA), Dr Brent Wood (University of Washington, Seattle, WA), Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL), Dr Christoph Röllig (Universitätskli​nikum Dresde...
by:EMJ | 155 views
07:49
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarab...
by:EMJ | 134 views
07:14
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) discusses a phase I study of AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, in IDH2-mut...
by:EMJ | 135 views

Top Tags



Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Oncologist 
Different type of MD 
Nurse 
Other oncology Professional 
Patient/Advocate 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.


username:   password: remember me

Sign In

Username:
Password:
Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)